ABSTRACT
With aging, the human prostate gland exhibits a startling propensity for both benign and malignant neoplasia. Estimates for 2004 predicted 230,110 new cases of prostate cancer in the United States, representing the majority (33%) of new cancer cases in men (excluding skin cancer). Currently, US males have a 1 in 6 lifetime risk of developing clinical prostate cancer, and prostate cancer is the second leading cause of cancer deaths in US men (29,900 deaths estimated for 2004).1
